Lantheus Holdings, Inc. $LNTH Stake Cut by William Blair Investment Management LLC

William Blair Investment Management LLC cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 522,177 shares of the medical equipment provider’s stock after selling 52,504 shares during the quarter. William Blair Investment Management LLC owned 0.79% of Lantheus worth $34,751,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Lantheus during the third quarter worth $1,847,000. American Assets Inc. bought a new position in Lantheus during the third quarter worth $872,000. Assetmark Inc. lifted its stake in Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after purchasing an additional 19,844 shares during the last quarter. Vanguard Group Inc. lifted its stake in Lantheus by 1.7% during the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Lantheus during the third quarter worth $3,866,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

NASDAQ:LNTH opened at $103.00 on Monday. The business’s 50-day moving average price is $83.62 and its 200 day moving average price is $71.86. The firm has a market cap of $6.71 billion, a P/E ratio of 24.82 and a beta of -0.08. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $103.89. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LNTH. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $99.71.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.